yingweiwo

ADCs

ADCs

ADCs related products

Structure Cat No. Product Name CAS No. Product Description
ADC Control Human IgG1-Deruxtecan (DAR 8) V97196 ADC Control Human IgG1-Deruxtecan (DAR 8) ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody that serves as an isotype control for the ADC Human IgG1-Deruxtecan, which inhibits DNA topoisomerase I.
Anti-CD22-NMS249 V94359 Anti-CD22-NMS249 Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC) composed of the humanized anti-CD22 antibody Pinatuzumab, a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor.
Exatecan Intermediate 3 V78751 Exatecan Intermediate 3 Exatecan Intermediate 3 is the intermediate of Exatecan.
FZ-AD005 V94122 FZ-AD005 FZ-AD005 is a DLL3-targeted ADC containing a novel anti-DLL3 antibody, FZ-A038, and a valine-alanine (Val-Ala) dipeptide linker.
Izeltabart (IMGC-936) V76158 Izeltabart (IMGC-936) 2642078-60-0 Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9.
KRAS degrader-1 V53069 KRAS degrader-1 2795275-59-9 KRAS degrader-1 (compound 1) is a potent KRAS degrader.
ORM-5029 V88375 ORM-5029 ORM-5029 is the first antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), which is a combination of the highly effective GSPT1 degrader SMol006 and Pertuzumab.
Raludotatug Deruxtecan V94455 Raludotatug Deruxtecan Raludotatug Deruxtecan (DS-6000) is a novel antibody-drug conjugate (ADC) targeting CDH6.
SMP-33693 V81404 SMP-33693 SMP-33693 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
SMP-88480 V81405 SMP-88480 SMP-88480 is an Antibody-Drug Conjugates (ADCs).
SMP-93566 V81406 SMP-93566 SMP-93566 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor suppressive effects on ovarian cancer, gastric cancer, and breast cancer.
Contact Us